#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Connectome-Wide Analysis Reveals Common Dimensional Reward Deficits Across Mood and Psychotic Disorders Objective Anhedonia is central to multiple psychiatric disorders and causes substantial disability.
1-1	0-15	Connectome-Wide	_
1-2	16-24	Analysis	_
1-3	25-32	Reveals	_
1-4	33-39	Common	_
1-5	40-51	Dimensional	_
1-6	52-58	Reward	_
1-7	59-67	Deficits	_
1-8	68-74	Across	_
1-9	75-79	Mood	_
1-10	80-83	and	_
1-11	84-93	Psychotic	_
1-12	94-103	Disorders	_
1-13	104-113	Objective	_
1-14	114-123	Anhedonia	_
1-15	124-126	is	_
1-16	127-134	central	_
1-17	135-137	to	_
1-18	138-146	multiple	_
1-19	147-158	psychiatric	_
1-20	159-168	disorders	_
1-21	169-172	and	_
1-22	173-179	causes	_
1-23	180-191	substantial	_
1-24	192-202	disability	_
1-25	203-204	.	_

Text=A dimensional conceptualization posits that anhedonia severity relates to a trans-diagnostic continuum of reward deficits in specific neural networks.
2-1	205-206	A	_
2-2	207-218	dimensional	_
2-3	219-236	conceptualization	_
2-4	237-243	posits	_
2-5	244-248	that	_
2-6	249-258	anhedonia	_
2-7	259-267	severity	_
2-8	268-275	relates	_
2-9	276-278	to	_
2-10	279-280	a	_
2-11	281-297	trans-diagnostic	_
2-12	298-307	continuum	_
2-13	308-310	of	_
2-14	311-317	reward	_
2-15	318-326	deficits	_
2-16	327-329	in	_
2-17	330-338	specific	_
2-18	339-345	neural	_
2-19	346-354	networks	_
2-20	355-356	.	_

Text=Prior investigations of functional connectivity related to anhedonia have focused on case-control comparisons in specific disorders, using region-specific seed-based analyses.
3-1	357-362	Prior	_
3-2	363-377	investigations	_
3-3	378-380	of	_
3-4	381-391	functional	_
3-5	392-404	connectivity	_
3-6	405-412	related	_
3-7	413-415	to	_
3-8	416-425	anhedonia	_
3-9	426-430	have	_
3-10	431-438	focused	_
3-11	439-441	on	_
3-12	442-454	case-control	_
3-13	455-466	comparisons	_
3-14	467-469	in	_
3-15	470-478	specific	_
3-16	479-488	disorders	_
3-17	489-490	,	_
3-18	491-496	using	_
3-19	497-512	region-specific	_
3-20	513-523	seed-based	_
3-21	524-532	analyses	_
3-22	533-534	.	_

Text=Here, the authors explore the entire functional connectome in relation to reward responsivity across a population of adults with hetereogenous psychopathology.
4-1	535-539	Here	_
4-2	540-541	,	_
4-3	542-545	the	_
4-4	546-553	authors	_
4-5	554-561	explore	_
4-6	562-565	the	_
4-7	566-572	entire	_
4-8	573-583	functional	_
4-9	584-594	connectome	_
4-10	595-597	in	_
4-11	598-606	relation	_
4-12	607-609	to	_
4-13	610-616	reward	_
4-14	617-629	responsivity	_
4-15	630-636	across	_
4-16	637-638	a	_
4-17	639-649	population	_
4-18	650-652	of	_
4-19	653-659	adults	_
4-20	660-664	with	_
4-21	665-678	hetereogenous	_
4-22	679-694	psychopathology	_
4-23	695-696	.	_

Text=Method In a sample of 225 adults from five diagnostic groups (major depressive disorder, n=32; bipolar disorder, n=50; schizophrenia, n=51, psychosis risk, n=39; and healthy controls, n=53), the authors conducted a connectome-wide analysis examining the relationship between a dimensional measure of reward responsivity (reward sensitivity subscale of the Behavioral Activation Scale) and resting-state functional connectivity using multivariate distance-based matrix regression.
5-1	697-703	Method	_
5-2	704-706	In	_
5-3	707-708	a	_
5-4	709-715	sample	_
5-5	716-718	of	_
5-6	719-722	225	_
5-7	723-729	adults	_
5-8	730-734	from	_
5-9	735-739	five	_
5-10	740-750	diagnostic	_
5-11	751-757	groups	_
5-12	758-759	(	_
5-13	760-765	major	_
5-14	766-776	depressive	_
5-15	777-785	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MovementDisorder
5-16	786-787	,	_
5-17	788-792	n=32	_
5-18	793-794	;	_
5-19	795-802	bipolar	_
5-20	803-811	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MovementDisorder
5-21	812-813	,	_
5-22	814-818	n=50	_
5-23	819-820	;	_
5-24	821-834	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-25	835-836	,	_
5-26	837-841	n=51	_
5-27	842-843	,	_
5-28	844-853	psychosis	_
5-29	854-858	risk	_
5-30	859-860	,	_
5-31	861-865	n=39	_
5-32	866-867	;	_
5-33	868-871	and	_
5-34	872-879	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-35	880-888	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-36	889-890	,	_
5-37	891-895	n=53	_
5-38	896-897	)	_
5-39	898-899	,	_
5-40	900-903	the	_
5-41	904-911	authors	_
5-42	912-921	conducted	_
5-43	922-923	a	_
5-44	924-939	connectome-wide	_
5-45	940-948	analysis	_
5-46	949-958	examining	_
5-47	959-962	the	_
5-48	963-975	relationship	_
5-49	976-983	between	_
5-50	984-985	a	_
5-51	986-997	dimensional	_
5-52	998-1005	measure	_
5-53	1006-1008	of	_
5-54	1009-1015	reward	_
5-55	1016-1028	responsivity	_
5-56	1029-1030	(	_
5-57	1031-1037	reward	_
5-58	1038-1049	sensitivity	_
5-59	1050-1058	subscale	_
5-60	1059-1061	of	_
5-61	1062-1065	the	_
5-62	1066-1076	Behavioral	_
5-63	1077-1087	Activation	_
5-64	1088-1093	Scale	_
5-65	1094-1095	)	_
5-66	1096-1099	and	_
5-67	1100-1113	resting-state	_
5-68	1114-1124	functional	_
5-69	1125-1137	connectivity	_
5-70	1138-1143	using	_
5-71	1144-1156	multivariate	_
5-72	1157-1171	distance-based	_
5-73	1172-1178	matrix	_
5-74	1179-1189	regression	_
5-75	1190-1191	.	_

Text=Results This connectome-wide analysis identified foci of dysconnectivity associated with reward responsivity in the nucleus accumbens (NAc), default mode network (DMN) and cingulo-opercular network (CON).
6-1	1192-1199	Results	_
6-2	1200-1204	This	_
6-3	1205-1220	connectome-wide	_
6-4	1221-1229	analysis	_
6-5	1230-1240	identified	_
6-6	1241-1245	foci	_
6-7	1246-1248	of	_
6-8	1249-1264	dysconnectivity	_
6-9	1265-1275	associated	_
6-10	1276-1280	with	_
6-11	1281-1287	reward	_
6-12	1288-1300	responsivity	_
6-13	1301-1303	in	_
6-14	1304-1307	the	_
6-15	1308-1315	nucleus	_
6-16	1316-1325	accumbens	_
6-17	1326-1327	(	_
6-18	1328-1331	NAc	_
6-19	1332-1333	)	_
6-20	1334-1335	,	_
6-21	1336-1343	default	_
6-22	1344-1348	mode	_
6-23	1349-1356	network	_
6-24	1357-1358	(	_
6-25	1359-1362	DMN	_
6-26	1363-1364	)	_
6-27	1365-1368	and	_
6-28	1369-1386	cingulo-opercular	_
6-29	1387-1394	network	_
6-30	1395-1396	(	_
6-31	1397-1400	CON	_
6-32	1401-1402	)	_
6-33	1403-1404	.	_

Text=Follow-up analyses revealed dysconnectivity among specific large-scale functional networks and their connectivity with the NAc.
7-1	1405-1414	Follow-up	_
7-2	1415-1423	analyses	_
7-3	1424-1432	revealed	_
7-4	1433-1448	dysconnectivity	_
7-5	1449-1454	among	_
7-6	1455-1463	specific	_
7-7	1464-1475	large-scale	_
7-8	1476-1486	functional	_
7-9	1487-1495	networks	_
7-10	1496-1499	and	_
7-11	1500-1505	their	_
7-12	1506-1518	connectivity	_
7-13	1519-1523	with	_
7-14	1524-1527	the	_
7-15	1528-1531	NAc	_
7-16	1532-1533	.	_

Text=Reward deficits were associated with decreased connectivity between the NAc and DMN and increased connectivity between the NAc and CON.
8-1	1534-1540	Reward	_
8-2	1541-1549	deficits	_
8-3	1550-1554	were	_
8-4	1555-1565	associated	_
8-5	1566-1570	with	_
8-6	1571-1580	decreased	_
8-7	1581-1593	connectivity	_
8-8	1594-1601	between	_
8-9	1602-1605	the	_
8-10	1606-1609	NAc	_
8-11	1610-1613	and	_
8-12	1614-1617	DMN	_
8-13	1618-1621	and	_
8-14	1622-1631	increased	_
8-15	1632-1644	connectivity	_
8-16	1645-1652	between	_
8-17	1653-1656	the	_
8-18	1657-1660	NAc	_
8-19	1661-1664	and	_
8-20	1665-1668	CON	_
8-21	1669-1670	.	_

Text=In addition, impaired reward responsivity was associated with DMN hyper-connectivity and diminished connectivity between DMN and CON.
9-1	1671-1673	In	_
9-2	1674-1682	addition	_
9-3	1683-1684	,	_
9-4	1685-1693	impaired	_
9-5	1694-1700	reward	_
9-6	1701-1713	responsivity	_
9-7	1714-1717	was	_
9-8	1718-1728	associated	_
9-9	1729-1733	with	_
9-10	1734-1737	DMN	_
9-11	1738-1756	hyper-connectivity	_
9-12	1757-1760	and	_
9-13	1761-1771	diminished	_
9-14	1772-1784	connectivity	_
9-15	1785-1792	between	_
9-16	1793-1796	DMN	_
9-17	1797-1800	and	_
9-18	1801-1804	CON	_
9-19	1805-1806	.	_

Text=Conclusions These results emphasize the centrality of the nucleus accumbens in the pathophysiology of reward deficits and suggest that dissociable patterns of connectivity among large-scale networks are critical to the neurobiology of reward dysfunction across clinical diagnostic categories.
10-1	1807-1818	Conclusions	_
10-2	1819-1824	These	_
10-3	1825-1832	results	_
10-4	1833-1842	emphasize	_
10-5	1843-1846	the	_
10-6	1847-1857	centrality	_
10-7	1858-1860	of	_
10-8	1861-1864	the	_
10-9	1865-1872	nucleus	_
10-10	1873-1882	accumbens	_
10-11	1883-1885	in	_
10-12	1886-1889	the	_
10-13	1890-1905	pathophysiology	_
10-14	1906-1908	of	_
10-15	1909-1915	reward	_
10-16	1916-1924	deficits	_
10-17	1925-1928	and	_
10-18	1929-1936	suggest	_
10-19	1937-1941	that	_
10-20	1942-1953	dissociable	_
10-21	1954-1962	patterns	_
10-22	1963-1965	of	_
10-23	1966-1978	connectivity	_
10-24	1979-1984	among	_
10-25	1985-1996	large-scale	_
10-26	1997-2005	networks	_
10-27	2006-2009	are	_
10-28	2010-2018	critical	_
10-29	2019-2021	to	_
10-30	2022-2025	the	_
10-31	2026-2038	neurobiology	_
10-32	2039-2041	of	_
10-33	2042-2048	reward	_
10-34	2049-2060	dysfunction	_
10-35	2061-2067	across	_
10-36	2068-2076	clinical	_
10-37	2077-2087	diagnostic	_
10-38	2088-2098	categories	_
10-39	2099-2100	.	_

Text=METHODS Participants For this study, 244 subjects were assessed at two half-day visits using a common imaging and phenotyping protocol.
11-1	2101-2108	METHODS	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
11-2	2109-2121	Participants	_
11-3	2122-2125	For	_
11-4	2126-2130	this	_
11-5	2131-2136	study	_
11-6	2137-2138	,	_
11-7	2139-2142	244	_
11-8	2143-2151	subjects	_
11-9	2152-2156	were	_
11-10	2157-2165	assessed	_
11-11	2166-2168	at	_
11-12	2169-2172	two	_
11-13	2173-2181	half-day	_
11-14	2182-2188	visits	_
11-15	2189-2194	using	_
11-16	2195-2196	a	_
11-17	2197-2203	common	_
11-18	2204-2211	imaging	_
11-19	2212-2215	and	_
11-20	2216-2227	phenotyping	_
11-21	2228-2236	protocol	_
11-22	2237-2238	.	_

Text=On the first visit, the Structured Clinical Interview for DSM-IV was conducted.
12-1	2239-2241	On	_
12-2	2242-2245	the	_
12-3	2246-2251	first	_
12-4	2252-2257	visit	_
12-5	2258-2259	,	_
12-6	2260-2263	the	_
12-7	2264-2274	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-8	2275-2283	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-9	2284-2293	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-10	2294-2297	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-11	2298-2304	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-12	2305-2308	was	_
12-13	2309-2318	conducted	_
12-14	2319-2320	.	_

Text=On the second visit, assessment of reward responsiveness and neuroimaging was conducted.
13-1	2321-2323	On	_
13-2	2324-2327	the	_
13-3	2328-2334	second	_
13-4	2335-2340	visit	_
13-5	2341-2342	,	_
13-6	2343-2353	assessment	_
13-7	2354-2356	of	_
13-8	2357-2363	reward	_
13-9	2364-2378	responsiveness	_
13-10	2379-2382	and	_
13-11	2383-2395	neuroimaging	_
13-12	2396-2399	was	_
13-13	2400-2409	conducted	_
13-14	2410-2411	.	_

Text=Subjects were enrolled if they met criteria for major depressive disorder, bipolar disorder, schizophrenia, were at genetic or clinical risk of psychosis (e.g., a first degree relative of an individual with a psychotic disorder or who met clinical high risk criteria for psychosis) or had no Axis I diagnosis (healthy controls).
14-1	2412-2420	Subjects	_
14-2	2421-2425	were	_
14-3	2426-2434	enrolled	_
14-4	2435-2437	if	_
14-5	2438-2442	they	_
14-6	2443-2446	met	_
14-7	2447-2455	criteria	_
14-8	2456-2459	for	_
14-9	2460-2465	major	_
14-10	2466-2476	depressive	_
14-11	2477-2485	disorder	_
14-12	2486-2487	,	_
14-13	2488-2495	bipolar	_
14-14	2496-2504	disorder	_
14-15	2505-2506	,	_
14-16	2507-2520	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
14-17	2521-2522	,	_
14-18	2523-2527	were	_
14-19	2528-2530	at	_
14-20	2531-2538	genetic	_
14-21	2539-2541	or	_
14-22	2542-2550	clinical	_
14-23	2551-2555	risk	_
14-24	2556-2558	of	_
14-25	2559-2568	psychosis	_
14-26	2569-2570	(	_
14-27	2571-2575	e.g.	_
14-28	2576-2577	,	_
14-29	2578-2579	a	_
14-30	2580-2585	first	_
14-31	2586-2592	degree	_
14-32	2593-2601	relative	_
14-33	2602-2604	of	_
14-34	2605-2607	an	_
14-35	2608-2618	individual	_
14-36	2619-2623	with	_
14-37	2624-2625	a	_
14-38	2626-2635	psychotic	_
14-39	2636-2644	disorder	_
14-40	2645-2647	or	_
14-41	2648-2651	who	_
14-42	2652-2655	met	_
14-43	2656-2664	clinical	_
14-44	2665-2669	high	_
14-45	2670-2674	risk	_
14-46	2675-2683	criteria	_
14-47	2684-2687	for	_
14-48	2688-2697	psychosis	_
14-49	2698-2699	)	_
14-50	2700-2702	or	_
14-51	2703-2706	had	_
14-52	2707-2709	no	_
14-53	2710-2714	Axis	_
14-54	2715-2716	I	_
14-55	2717-2726	diagnosis	_
14-56	2727-2728	(	_
14-57	2729-2736	healthy	_
14-58	2737-2745	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
14-59	2746-2747	)	_
14-60	2748-2749	.	_

Text=Following quality assurance, the final sample included in the analysis comprised 225 subjects (Table 1).
15-1	2750-2759	Following	_
15-2	2760-2767	quality	_
15-3	2768-2777	assurance	_
15-4	2778-2779	,	_
15-5	2780-2783	the	_
15-6	2784-2789	final	_
15-7	2790-2796	sample	_
15-8	2797-2805	included	_
15-9	2806-2808	in	_
15-10	2809-2812	the	_
15-11	2813-2821	analysis	_
15-12	2822-2831	comprised	_
15-13	2832-2835	225	_
15-14	2836-2844	subjects	_
15-15	2845-2846	(	_
15-16	2847-2852	Table	_
15-17	2853-2854	1	_
15-18	2855-2856	)	_
15-19	2857-2858	.	_

Text=For a list of medications by class, see Table S1.
16-1	2859-2862	For	_
16-2	2863-2864	a	_
16-3	2865-2869	list	_
16-4	2870-2872	of	_
16-5	2873-2884	medications	_
16-6	2885-2887	by	_
16-7	2888-2893	class	_
16-8	2894-2895	,	_
16-9	2896-2899	see	_
16-10	2900-2905	Table	_
16-11	2906-2908	S1	_
16-12	2909-2910	.	_

Text=The University of Pennsylvania Institutional Review Board approved all study procedures and all subjects gave informed consent in writing.
17-1	2911-2914	The	_
17-2	2915-2925	University	_
17-3	2926-2928	of	_
17-4	2929-2941	Pennsylvania	_
17-5	2942-2955	Institutional	_
17-6	2956-2962	Review	_
17-7	2963-2968	Board	_
17-8	2969-2977	approved	_
17-9	2978-2981	all	_
17-10	2982-2987	study	_
17-11	2988-2998	procedures	_
17-12	2999-3002	and	_
17-13	3003-3006	all	_
17-14	3007-3015	subjects	_
17-15	3016-3020	gave	_
17-16	3021-3029	informed	_
17-17	3030-3037	consent	_
17-18	3038-3040	in	_
17-19	3041-3048	writing	_
17-20	3049-3050	.	_

Text=See Supplementary Methods for additional details.
18-1	3051-3054	See	_
18-2	3055-3068	Supplementary	_
18-3	3069-3076	Methods	_
18-4	3077-3080	for	_
18-5	3081-3091	additional	_
18-6	3092-3099	details	_
18-7	3100-3101	.	_

Text=Dimensional assessment of reward responsiveness To assess reward-related functioning, the Behavioral Activation Scale (BAS) including the reward sensitivity subscale (BAS Reward) was administered.
19-1	3102-3113	Dimensional	_
19-2	3114-3124	assessment	_
19-3	3125-3127	of	_
19-4	3128-3134	reward	_
19-5	3135-3149	responsiveness	_
19-6	3150-3152	To	_
19-7	3153-3159	assess	_
19-8	3160-3174	reward-related	_
19-9	3175-3186	functioning	_
19-10	3187-3188	,	_
19-11	3189-3192	the	_
19-12	3193-3203	Behavioral	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale
19-13	3204-3214	Activation	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale
19-14	3215-3220	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale
19-15	3221-3222	(	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale
19-16	3223-3226	BAS	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale
19-17	3227-3228	)	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale
19-18	3229-3238	including	_
19-19	3239-3242	the	_
19-20	3243-3249	reward	_
19-21	3250-3261	sensitivity	_
19-22	3262-3270	subscale	_
19-23	3271-3272	(	_
19-24	3273-3276	BAS	_
19-25	3277-3283	Reward	_
19-26	3284-3285	)	_
19-27	3286-3289	was	_
19-28	3290-3302	administered	_
19-29	3303-3304	.	_

Text=BAS Reward was chosen as it has been identified as a transdiagnostic measure of reward responsivity and used to index anhedonia.
20-1	3305-3308	BAS	_
20-2	3309-3315	Reward	_
20-3	3316-3319	was	_
20-4	3320-3326	chosen	_
20-5	3327-3329	as	_
20-6	3330-3332	it	_
20-7	3333-3336	has	_
20-8	3337-3341	been	_
20-9	3342-3352	identified	_
20-10	3353-3355	as	_
20-11	3356-3357	a	_
20-12	3358-3373	transdiagnostic	_
20-13	3374-3381	measure	_
20-14	3382-3384	of	_
20-15	3385-3391	reward	_
20-16	3392-3404	responsivity	_
20-17	3405-3408	and	_
20-18	3409-3413	used	_
20-19	3414-3416	to	_
20-20	3417-3422	index	_
20-21	3423-3432	anhedonia	_
20-22	3433-3434	.	_

Text=The scale captures a broad range of reward functioning, and is useful for dimensional analyses across both clinical and non-clinical samples (Figure S1).
21-1	3435-3438	The	_
21-2	3439-3444	scale	_
21-3	3445-3453	captures	_
21-4	3454-3455	a	_
21-5	3456-3461	broad	_
21-6	3462-3467	range	_
21-7	3468-3470	of	_
21-8	3471-3477	reward	_
21-9	3478-3489	functioning	_
21-10	3490-3491	,	_
21-11	3492-3495	and	_
21-12	3496-3498	is	_
21-13	3499-3505	useful	_
21-14	3506-3509	for	_
21-15	3510-3521	dimensional	_
21-16	3522-3530	analyses	_
21-17	3531-3537	across	_
21-18	3538-3542	both	_
21-19	3543-3551	clinical	_
21-20	3552-3555	and	_
21-21	3556-3568	non-clinical	_
21-22	3569-3576	samples	_
21-23	3577-3578	(	_
21-24	3579-3585	Figure	_
21-25	3586-3588	S1	_
21-26	3589-3590	)	_
21-27	3591-3592	.	_

Text=As the initial descriptions of the BAS factor structure considered healthy young adults, we conducted a factor analysis on item-level data to confirm previously identified subfactors including BAS Reward in our clinical sample (Table S2).
22-1	3593-3595	As	_
22-2	3596-3599	the	_
22-3	3600-3607	initial	_
22-4	3608-3620	descriptions	_
22-5	3621-3623	of	_
22-6	3624-3627	the	_
22-7	3628-3631	BAS	_
22-8	3632-3638	factor	_
22-9	3639-3648	structure	_
22-10	3649-3659	considered	_
22-11	3660-3667	healthy	_
22-12	3668-3673	young	_
22-13	3674-3680	adults	_
22-14	3681-3682	,	_
22-15	3683-3685	we	_
22-16	3686-3695	conducted	_
22-17	3696-3697	a	_
22-18	3698-3704	factor	_
22-19	3705-3713	analysis	_
22-20	3714-3716	on	_
22-21	3717-3727	item-level	_
22-22	3728-3732	data	_
22-23	3733-3735	to	_
22-24	3736-3743	confirm	_
22-25	3744-3754	previously	_
22-26	3755-3765	identified	_
22-27	3766-3776	subfactors	_
22-28	3777-3786	including	_
22-29	3787-3790	BAS	_
22-30	3791-3797	Reward	_
22-31	3798-3800	in	_
22-32	3801-3804	our	_
22-33	3805-3813	clinical	_
22-34	3814-3820	sample	_
22-35	3821-3822	(	_
22-36	3823-3828	Table	_
22-37	3829-3831	S2	_
22-38	3832-3833	)	_
22-39	3834-3835	.	_

Text=Image acquisition and processing All magnetic resonance imaging data were acquired on the same Siemens 3T MRI scanner using the same imaging sequences, as detailed in Supplementary Methods.
23-1	3836-3841	Image	_
23-2	3842-3853	acquisition	_
23-3	3854-3857	and	_
23-4	3858-3868	processing	_
23-5	3869-3872	All	_
23-6	3873-3881	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
23-7	3882-3891	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
23-8	3892-3899	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
23-9	3900-3904	data	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
23-10	3905-3909	were	_
23-11	3910-3918	acquired	_
23-12	3919-3921	on	_
23-13	3922-3925	the	_
23-14	3926-3930	same	_
23-15	3931-3938	Siemens	_
23-16	3939-3941	3T	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
23-17	3942-3945	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
23-18	3946-3953	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
23-19	3954-3959	using	_
23-20	3960-3963	the	_
23-21	3964-3968	same	_
23-22	3969-3976	imaging	_
23-23	3977-3986	sequences	_
23-24	3987-3988	,	_
23-25	3989-3991	as	_
23-26	3992-4000	detailed	_
23-27	4001-4003	in	_
23-28	4004-4017	Supplementary	_
23-29	4018-4025	Methods	_
23-30	4026-4027	.	_

Text=Resting-state fMRI bold-oxygen-level dependent (BOLD) time series data were processed to correct image distortion and to minimize the influence of participant motion, transformed into a standard anatomical brain space (Montreal Neurological Institute, MNI) and downsampled to a lower spatial resolution prior to CWAS.
24-1	4028-4041	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
24-2	4042-4046	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
24-3	4047-4064	bold-oxygen-level	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
24-4	4065-4074	dependent	_
24-5	4075-4076	(	_
24-6	4077-4081	BOLD	_
24-7	4082-4083	)	_
24-8	4084-4088	time	_
24-9	4089-4095	series	_
24-10	4096-4100	data	_
24-11	4101-4105	were	_
24-12	4106-4115	processed	_
24-13	4116-4118	to	_
24-14	4119-4126	correct	_
24-15	4127-4132	image	_
24-16	4133-4143	distortion	_
24-17	4144-4147	and	_
24-18	4148-4150	to	_
24-19	4151-4159	minimize	_
24-20	4160-4163	the	_
24-21	4164-4173	influence	_
24-22	4174-4176	of	_
24-23	4177-4188	participant	_
24-24	4189-4195	motion	_
24-25	4196-4197	,	_
24-26	4198-4209	transformed	_
24-27	4210-4214	into	_
24-28	4215-4216	a	_
24-29	4217-4225	standard	_
24-30	4226-4236	anatomical	_
24-31	4237-4242	brain	_
24-32	4243-4248	space	_
24-33	4249-4250	(	_
24-34	4251-4259	Montreal	_
24-35	4260-4272	Neurological	_
24-36	4273-4282	Institute	_
24-37	4283-4284	,	_
24-38	4285-4288	MNI	_
24-39	4289-4290	)	_
24-40	4291-4294	and	_
24-41	4295-4306	downsampled	_
24-42	4307-4309	to	_
24-43	4310-4311	a	_
24-44	4312-4317	lower	_
24-45	4318-4325	spatial	_
24-46	4326-4336	resolution	_
24-47	4337-4342	prior	_
24-48	4343-4345	to	_
24-49	4346-4350	CWAS	_
24-50	4351-4352	.	_

Text=Connectome-Wide Association Study (CWAS) using MDMR MDMR relating reward sensitivity to whole-brain connectivity patterns was conducted in three steps (Figure 1).
25-1	4353-4368	Connectome-Wide	_
25-2	4369-4380	Association	_
25-3	4381-4386	Study	_
25-4	4387-4388	(	_
25-5	4389-4393	CWAS	_
25-6	4394-4395	)	_
25-7	4396-4401	using	_
25-8	4402-4406	MDMR	http://maven.renci.org/NeuroBridge/neurobridge#SchizophreniformDisorder
25-9	4407-4411	MDMR	http://maven.renci.org/NeuroBridge/neurobridge#SchizophreniformDisorder
25-10	4412-4420	relating	_
25-11	4421-4427	reward	_
25-12	4428-4439	sensitivity	_
25-13	4440-4442	to	_
25-14	4443-4454	whole-brain	_
25-15	4455-4467	connectivity	_
25-16	4468-4476	patterns	_
25-17	4477-4480	was	_
25-18	4481-4490	conducted	_
25-19	4491-4493	in	_
25-20	4494-4499	three	_
25-21	4500-4505	steps	_
25-22	4506-4507	(	_
25-23	4508-4514	Figure	_
25-24	4515-4516	1	_
25-25	4517-4518	)	_
25-26	4519-4520	.	_

Text=In the first step, the processed voxelwise subject resting-state fMRI data were used to conduct a seed-based connectivity analysis at each gray matter voxel.
26-1	4521-4523	In	_
26-2	4524-4527	the	_
26-3	4528-4533	first	_
26-4	4534-4538	step	_
26-5	4539-4540	,	_
26-6	4541-4544	the	_
26-7	4545-4554	processed	_
26-8	4555-4564	voxelwise	_
26-9	4565-4572	subject	_
26-10	4573-4586	resting-state	_
26-11	4587-4591	fMRI	_
26-12	4592-4596	data	_
26-13	4597-4601	were	_
26-14	4602-4606	used	_
26-15	4607-4609	to	_
26-16	4610-4617	conduct	_
26-17	4618-4619	a	_
26-18	4620-4630	seed-based	_
26-19	4631-4643	connectivity	_
26-20	4644-4652	analysis	_
26-21	4653-4655	at	_
26-22	4656-4660	each	_
26-23	4661-4665	gray	_
26-24	4666-4672	matter	_
26-25	4673-4678	voxel	_
26-26	4679-4680	.	_

Text=This step calculates the Pearson ’ s correlation between each voxel ’ s BOLD time series and that of every other voxel within gray matter.
27-1	4681-4685	This	_
27-2	4686-4690	step	_
27-3	4691-4701	calculates	_
27-4	4702-4705	the	_
27-5	4706-4713	Pearson	_
27-6	4714-4715	’	_
27-7	4716-4717	s	_
27-8	4718-4729	correlation	_
27-9	4730-4737	between	_
27-10	4738-4742	each	_
27-11	4743-4748	voxel	_
27-12	4749-4750	’	_
27-13	4751-4752	s	_
27-14	4753-4757	BOLD	_
27-15	4758-4762	time	_
27-16	4763-4769	series	_
27-17	4770-4773	and	_
27-18	4774-4778	that	_
27-19	4779-4781	of	_
27-20	4782-4787	every	_
27-21	4788-4793	other	_
27-22	4794-4799	voxel	_
27-23	4800-4806	within	_
27-24	4807-4811	gray	_
27-25	4812-4818	matter	_
27-26	4819-4820	.	_

Text=In the second step, the overall pattern of connectivity for each voxel was compared between the subjects using a distance metric.
28-1	4821-4823	In	_
28-2	4824-4827	the	_
28-3	4828-4834	second	_
28-4	4835-4839	step	_
28-5	4840-4841	,	_
28-6	4842-4845	the	_
28-7	4846-4853	overall	_
28-8	4854-4861	pattern	_
28-9	4862-4864	of	_
28-10	4865-4877	connectivity	_
28-11	4878-4881	for	_
28-12	4882-4886	each	_
28-13	4887-4892	voxel	_
28-14	4893-4896	was	_
28-15	4897-4905	compared	_
28-16	4906-4913	between	_
28-17	4914-4917	the	_
28-18	4918-4926	subjects	_
28-19	4927-4932	using	_
28-20	4933-4934	a	_
28-21	4935-4943	distance	_
28-22	4944-4950	metric	_
28-23	4951-4952	.	_

Text=The distance metric quantifies the similarity in the pattern of connectivity between each pair of subjects.
29-1	4953-4956	The	_
29-2	4957-4965	distance	_
29-3	4966-4972	metric	_
29-4	4973-4983	quantifies	_
29-5	4984-4987	the	_
29-6	4988-4998	similarity	_
29-7	4999-5001	in	_
29-8	5002-5005	the	_
29-9	5006-5013	pattern	_
29-10	5014-5016	of	_
29-11	5017-5029	connectivity	_
29-12	5030-5037	between	_
29-13	5038-5042	each	_
29-14	5043-5047	pair	_
29-15	5048-5050	of	_
29-16	5051-5059	subjects	_
29-17	5060-5061	.	_

Text=Finally, in the third step, MDMR was used to test how well the dimensional variable of interest (BAS Reward) explained the distances between each subject ’ s pattern of connectivity at that seed voxel, while controlling for the effects of nuisance covariates such as clinical group status, age, sex, and in-scanner motion.
30-1	5062-5069	Finally	_
30-2	5070-5071	,	_
30-3	5072-5074	in	_
30-4	5075-5078	the	_
30-5	5079-5084	third	_
30-6	5085-5089	step	_
30-7	5090-5091	,	_
30-8	5092-5096	MDMR	_
30-9	5097-5100	was	_
30-10	5101-5105	used	_
30-11	5106-5108	to	_
30-12	5109-5113	test	_
30-13	5114-5117	how	_
30-14	5118-5122	well	_
30-15	5123-5126	the	_
30-16	5127-5138	dimensional	_
30-17	5139-5147	variable	_
30-18	5148-5150	of	_
30-19	5151-5159	interest	_
30-20	5160-5161	(	_
30-21	5162-5165	BAS	_
30-22	5166-5172	Reward	_
30-23	5173-5174	)	_
30-24	5175-5184	explained	_
30-25	5185-5188	the	_
30-26	5189-5198	distances	_
30-27	5199-5206	between	_
30-28	5207-5211	each	_
30-29	5212-5219	subject	_
30-30	5220-5221	’	_
30-31	5222-5223	s	_
30-32	5224-5231	pattern	_
30-33	5232-5234	of	_
30-34	5235-5247	connectivity	_
30-35	5248-5250	at	_
30-36	5251-5255	that	_
30-37	5256-5260	seed	_
30-38	5261-5266	voxel	_
30-39	5267-5268	,	_
30-40	5269-5274	while	_
30-41	5275-5286	controlling	_
30-42	5287-5290	for	_
30-43	5291-5294	the	_
30-44	5295-5302	effects	_
30-45	5303-5305	of	_
30-46	5306-5314	nuisance	_
30-47	5315-5325	covariates	_
30-48	5326-5330	such	_
30-49	5331-5333	as	_
30-50	5334-5342	clinical	_
30-51	5343-5348	group	_
30-52	5349-5355	status	_
30-53	5356-5357	,	_
30-54	5358-5361	age	_
30-55	5362-5363	,	_
30-56	5364-5367	sex	_
30-57	5368-5369	,	_
30-58	5370-5373	and	_
30-59	5374-5384	in-scanner	_
30-60	5385-5391	motion	_
30-61	5392-5393	.	_

Text=This MDMR procedure identified voxels where BAS Reward affected the overall pattern of connectivity.
31-1	5394-5398	This	_
31-2	5399-5403	MDMR	_
31-3	5404-5413	procedure	_
31-4	5414-5424	identified	_
31-5	5425-5431	voxels	_
31-6	5432-5437	where	_
31-7	5438-5441	BAS	_
31-8	5442-5448	Reward	_
31-9	5449-5457	affected	_
31-10	5458-5461	the	_
31-11	5462-5469	overall	_
31-12	5470-5477	pattern	_
31-13	5478-5480	of	_
31-14	5481-5493	connectivity	_
31-15	5494-5495	.	_

Text=As in Shehzad et al., the false positive error rate (type I error) of MDMR was controlled using cluster-correction with a voxel height of z> 1.64, and utilized a cluster-extent probability threshold P <0.01.
32-1	5496-5498	As	_
32-2	5499-5501	in	_
32-3	5502-5509	Shehzad	_
32-4	5510-5512	et	_
32-5	5513-5516	al.	_
32-6	5517-5518	,	_
32-7	5519-5522	the	_
32-8	5523-5528	false	_
32-9	5529-5537	positive	_
32-10	5538-5543	error	_
32-11	5544-5548	rate	_
32-12	5549-5550	(	_
32-13	5551-5555	type	_
32-14	5556-5557	I	_
32-15	5558-5563	error	_
32-16	5564-5565	)	_
32-17	5566-5568	of	_
32-18	5569-5573	MDMR	http://maven.renci.org/NeuroBridge/neurobridge#Thing
32-19	5574-5577	was	_
32-20	5578-5588	controlled	_
32-21	5589-5594	using	_
32-22	5595-5613	cluster-correction	_
32-23	5614-5618	with	_
32-24	5619-5620	a	_
32-25	5621-5626	voxel	_
32-26	5627-5633	height	_
32-27	5634-5636	of	_
32-28	5637-5638	z	_
32-29	5639-5640	>	_
32-30	5641-5645	1.64	_
32-31	5646-5647	,	_
32-32	5648-5651	and	_
32-33	5652-5660	utilized	_
32-34	5661-5662	a	_
32-35	5663-5677	cluster-extent	_
32-36	5678-5689	probability	_
32-37	5690-5699	threshold	_
32-38	5700-5701	P	_
32-39	5702-5703	<	_
32-40	5704-5708	0.01	_
32-41	5709-5710	.	_

Text=Cortical projections of MDMR statistical maps were displayed using Caret.
33-1	5711-5719	Cortical	_
33-2	5720-5731	projections	_
33-3	5732-5734	of	_
33-4	5735-5739	MDMR	_
33-5	5740-5751	statistical	_
33-6	5752-5756	maps	_
33-7	5757-5761	were	_
33-8	5762-5771	displayed	_
33-9	5772-5777	using	_
33-10	5778-5783	Caret	_
33-11	5784-5785	.	_

Text=(See Supplementary Methods for additional details).
34-1	5786-5787	(	_
34-2	5788-5791	See	_
34-3	5792-5805	Supplementary	_
34-4	5806-5813	Methods	_
34-5	5814-5817	for	_
34-6	5818-5828	additional	_
34-7	5829-5836	details	_
34-8	5837-5838	)	_
34-9	5839-5840	.	_

Text=Follow up seed-based analyses Although MDMR identifies clusters where the overall multivariate pattern of connectivity is dimensionally related to BAS Reward, it does not describe the specific pattern of connectivity that is driving the significant result.
35-1	5841-5847	Follow	_
35-2	5848-5850	up	_
35-3	5851-5861	seed-based	_
35-4	5862-5870	analyses	_
35-5	5871-5879	Although	_
35-6	5880-5884	MDMR	_
35-7	5885-5895	identifies	_
35-8	5896-5904	clusters	_
35-9	5905-5910	where	_
35-10	5911-5914	the	_
35-11	5915-5922	overall	_
35-12	5923-5935	multivariate	_
35-13	5936-5943	pattern	_
35-14	5944-5946	of	_
35-15	5947-5959	connectivity	_
35-16	5960-5962	is	_
35-17	5963-5976	dimensionally	_
35-18	5977-5984	related	_
35-19	5985-5987	to	_
35-20	5988-5991	BAS	_
35-21	5992-5998	Reward	_
35-22	5999-6000	,	_
35-23	6001-6003	it	_
35-24	6004-6008	does	_
35-25	6009-6012	not	_
35-26	6013-6021	describe	_
35-27	6022-6025	the	_
35-28	6026-6034	specific	_
35-29	6035-6042	pattern	_
35-30	6043-6045	of	_
35-31	6046-6058	connectivity	_
35-32	6059-6063	that	_
35-33	6064-6066	is	_
35-34	6067-6074	driving	_
35-35	6075-6078	the	_
35-36	6079-6090	significant	_
35-37	6091-6097	result	_
35-38	6098-6099	.	_

Text=As in prior studies, we conducted post-hoc seed-based analyses from each cluster returned by MDMR, followed by network analyses of these regions (described below).
36-1	6100-6102	As	_
36-2	6103-6105	in	_
36-3	6106-6111	prior	_
36-4	6112-6119	studies	_
36-5	6120-6121	,	_
36-6	6122-6124	we	_
36-7	6125-6134	conducted	_
36-8	6135-6143	post-hoc	_
36-9	6144-6154	seed-based	_
36-10	6155-6163	analyses	_
36-11	6164-6168	from	_
36-12	6169-6173	each	_
36-13	6174-6181	cluster	_
36-14	6182-6190	returned	_
36-15	6191-6193	by	_
36-16	6194-6198	MDMR	_
36-17	6199-6200	,	_
36-18	6201-6209	followed	_
36-19	6210-6212	by	_
36-20	6213-6220	network	_
36-21	6221-6229	analyses	_
36-22	6230-6232	of	_
36-23	6233-6238	these	_
36-24	6239-6246	regions	_
36-25	6247-6248	(	_
36-26	6249-6258	described	_
36-27	6259-6264	below	_
36-28	6265-6266	)	_
36-29	6267-6268	.	_

Text=Group-level seed analyses included covariates as above.
37-1	6269-6280	Group-level	_
37-2	6281-6285	seed	_
37-3	6286-6294	analyses	_
37-4	6295-6303	included	_
37-5	6304-6314	covariates	_
37-6	6315-6317	as	_
37-7	6318-6323	above	_
37-8	6324-6325	.	_

Text=These follow-up analyses subsequent to MDMR are applied descriptively, as the seeds were selected based on the significance of the MDMR result.
38-1	6326-6331	These	_
38-2	6332-6341	follow-up	_
38-3	6342-6350	analyses	_
38-4	6351-6361	subsequent	_
38-5	6362-6364	to	_
38-6	6365-6369	MDMR	_
38-7	6370-6373	are	_
38-8	6374-6381	applied	_
38-9	6382-6395	descriptively	_
38-10	6396-6397	,	_
38-11	6398-6400	as	_
38-12	6401-6404	the	_
38-13	6405-6410	seeds	_
38-14	6411-6415	were	_
38-15	6416-6424	selected	_
38-16	6425-6430	based	_
38-17	6431-6433	on	_
38-18	6434-6437	the	_
38-19	6438-6450	significance	_
38-20	6451-6453	of	_
38-21	6454-6457	the	_
38-22	6458-6462	MDMR	_
38-23	6463-6469	result	_
38-24	6470-6471	.	_

Text=Further details are described in the Supplementary Methods.
39-1	6472-6479	Further	_
39-2	6480-6487	details	_
39-3	6488-6491	are	_
39-4	6492-6501	described	_
39-5	6502-6504	in	_
39-6	6505-6508	the	_
39-7	6509-6522	Supplementary	_
39-8	6523-6530	Methods	_
39-9	6531-6532	.	_

Text=Network construction and analysis In order to summarize the observed pairwise interactions among the implicated brain regions, we evaluated the data within a network framework.
40-1	6533-6540	Network	_
40-2	6541-6553	construction	_
40-3	6554-6557	and	_
40-4	6558-6566	analysis	_
40-5	6567-6569	In	_
40-6	6570-6575	order	_
40-7	6576-6578	to	_
40-8	6579-6588	summarize	_
40-9	6589-6592	the	_
40-10	6593-6601	observed	_
40-11	6602-6610	pairwise	_
40-12	6611-6623	interactions	_
40-13	6624-6629	among	_
40-14	6630-6633	the	_
40-15	6634-6644	implicated	_
40-16	6645-6650	brain	_
40-17	6651-6658	regions	_
40-18	6659-6660	,	_
40-19	6661-6663	we	_
40-20	6664-6673	evaluated	_
40-21	6674-6677	the	_
40-22	6678-6682	data	_
40-23	6683-6689	within	_
40-24	6690-6691	a	_
40-25	6692-6699	network	_
40-26	6700-6709	framework	_
40-27	6710-6711	.	_

Text=We constructed a graph of cortical nodes consisting of clusters identified by MDMR.
41-1	6712-6714	We	_
41-2	6715-6726	constructed	_
41-3	6727-6728	a	_
41-4	6729-6734	graph	_
41-5	6735-6737	of	_
41-6	6738-6746	cortical	_
41-7	6747-6752	nodes	_
41-8	6753-6763	consisting	_
41-9	6764-6766	of	_
41-10	6767-6775	clusters	_
41-11	6776-6786	identified	_
41-12	6787-6789	by	_
41-13	6790-6794	MDMR	_
41-14	6795-6796	.	_

Text=As in prior work, subcortical nodes such as the NAc were not included in detecting cortical modules.
42-1	6797-6799	As	_
42-2	6800-6802	in	_
42-3	6803-6808	prior	_
42-4	6809-6813	work	_
42-5	6814-6815	,	_
42-6	6816-6827	subcortical	_
42-7	6828-6833	nodes	_
42-8	6834-6838	such	_
42-9	6839-6841	as	_
42-10	6842-6845	the	_
42-11	6846-6849	NAc	_
42-12	6850-6854	were	_
42-13	6855-6858	not	_
42-14	6859-6867	included	_
42-15	6868-6870	in	_
42-16	6871-6880	detecting	_
42-17	6881-6889	cortical	_
42-18	6890-6897	modules	_
42-19	6898-6899	.	_

Text=The graph was separated into distinct network modules using community detection techniques (described in Supplementary Methods).
43-1	6900-6903	The	_
43-2	6904-6909	graph	_
43-3	6910-6913	was	_
43-4	6914-6923	separated	_
43-5	6924-6928	into	_
43-6	6929-6937	distinct	_
43-7	6938-6945	network	_
43-8	6946-6953	modules	_
43-9	6954-6959	using	_
43-10	6960-6969	community	_
43-11	6970-6979	detection	_
43-12	6980-6990	techniques	_
43-13	6991-6992	(	_
43-14	6993-7002	described	_
43-15	7003-7005	in	_
43-16	7006-7019	Supplementary	_
43-17	7020-7027	Methods	_
43-18	7028-7029	)	_
43-19	7030-7031	.	_

Text=Differences in connectivity among the cortical modules and with the NAc were investigated using measures of within-network and between network connectivity.
44-1	7032-7043	Differences	_
44-2	7044-7046	in	_
44-3	7047-7059	connectivity	_
44-4	7060-7065	among	_
44-5	7066-7069	the	_
44-6	7070-7078	cortical	_
44-7	7079-7086	modules	_
44-8	7087-7090	and	_
44-9	7091-7095	with	_
44-10	7096-7099	the	_
44-11	7100-7103	NAc	_
44-12	7104-7108	were	_
44-13	7109-7121	investigated	_
44-14	7122-7127	using	_
44-15	7128-7136	measures	_
44-16	7137-7139	of	_
44-17	7140-7154	within-network	_
44-18	7155-7158	and	_
44-19	7159-7166	between	_
44-20	7167-7174	network	_
44-21	7175-7187	connectivity	_
44-22	7188-7189	.	_

Text=Within-network connectivity was defined as the mean correlation strength of all edges within a network module.
45-1	7190-7204	Within-network	_
45-2	7205-7217	connectivity	_
45-3	7218-7221	was	_
45-4	7222-7229	defined	_
45-5	7230-7232	as	_
45-6	7233-7236	the	_
45-7	7237-7241	mean	_
45-8	7242-7253	correlation	_
45-9	7254-7262	strength	_
45-10	7263-7265	of	_
45-11	7266-7269	all	_
45-12	7270-7275	edges	_
45-13	7276-7282	within	_
45-14	7283-7284	a	_
45-15	7285-7292	network	_
45-16	7293-7299	module	_
45-17	7300-7301	.	_

Text=In contrast, between-network connectivity was defined on a pairwise basis as the mean strength of edges between nodes within a network module and nodes outside the module.
46-1	7302-7304	In	_
46-2	7305-7313	contrast	_
46-3	7314-7315	,	_
46-4	7316-7331	between-network	_
46-5	7332-7344	connectivity	_
46-6	7345-7348	was	_
46-7	7349-7356	defined	_
46-8	7357-7359	on	_
46-9	7360-7361	a	_
46-10	7362-7370	pairwise	_
46-11	7371-7376	basis	_
46-12	7377-7379	as	_
46-13	7380-7383	the	_
46-14	7384-7388	mean	_
46-15	7389-7397	strength	_
46-16	7398-7400	of	_
46-17	7401-7406	edges	_
46-18	7407-7414	between	_
46-19	7415-7420	nodes	_
46-20	7421-7427	within	_
46-21	7428-7429	a	_
46-22	7430-7437	network	_
46-23	7438-7444	module	_
46-24	7445-7448	and	_
46-25	7449-7454	nodes	_
46-26	7455-7462	outside	_
46-27	7463-7466	the	_
46-28	7467-7473	module	_
46-29	7474-7475	.	_

Text=The relationship of BAS Reward to these connectivity measures was examined using linear regression, with covariates as detailed above.
47-1	7476-7479	The	_
47-2	7480-7492	relationship	_
47-3	7493-7495	of	_
47-4	7496-7499	BAS	_
47-5	7500-7506	Reward	_
47-6	7507-7509	to	_
47-7	7510-7515	these	_
47-8	7516-7528	connectivity	_
47-9	7529-7537	measures	_
47-10	7538-7541	was	_
47-11	7542-7550	examined	_
47-12	7551-7556	using	_
47-13	7557-7563	linear	_
47-14	7564-7574	regression	_
47-15	7575-7576	,	_
47-16	7577-7581	with	_
47-17	7582-7592	covariates	_
47-18	7593-7595	as	_
47-19	7596-7604	detailed	_
47-20	7605-7610	above	_
47-21	7611-7612	.	_

Text=Supplementary analyses To evaluate within-group dimensional effects, we conducted separate analyses examining network-level associations for each diagnostic group and specific sub-groups, as well as for a psychopathology-only sample that excluded healthy controls.
48-1	7613-7626	Supplementary	_
48-2	7627-7635	analyses	_
48-3	7636-7638	To	_
48-4	7639-7647	evaluate	_
48-5	7648-7660	within-group	_
48-6	7661-7672	dimensional	_
48-7	7673-7680	effects	_
48-8	7681-7682	,	_
48-9	7683-7685	we	_
48-10	7686-7695	conducted	_
48-11	7696-7704	separate	_
48-12	7705-7713	analyses	_
48-13	7714-7723	examining	_
48-14	7724-7737	network-level	_
48-15	7738-7750	associations	_
48-16	7751-7754	for	_
48-17	7755-7759	each	_
48-18	7760-7770	diagnostic	_
48-19	7771-7776	group	_
48-20	7777-7780	and	_
48-21	7781-7789	specific	_
48-22	7790-7800	sub-groups	_
48-23	7801-7802	,	_
48-24	7803-7805	as	_
48-25	7806-7810	well	_
48-26	7811-7813	as	_
48-27	7814-7817	for	_
48-28	7818-7819	a	_
48-29	7820-7840	psychopathology-only	_
48-30	7841-7847	sample	_
48-31	7848-7852	that	_
48-32	7853-7861	excluded	_
48-33	7862-7869	healthy	_
48-34	7870-7878	controls	_
48-35	7879-7880	.	_

Text=Additionally, we explored differences in network-level measures among categorical diagnostic groups.
49-1	7881-7893	Additionally	_
49-2	7894-7895	,	_
49-3	7896-7898	we	_
49-4	7899-7907	explored	_
49-5	7908-7919	differences	_
49-6	7920-7922	in	_
49-7	7923-7936	network-level	_
49-8	7937-7945	measures	_
49-9	7946-7951	among	_
49-10	7952-7963	categorical	_
49-11	7964-7974	diagnostic	_
49-12	7975-7981	groups	_
49-13	7982-7983	.	_

Text=Furthermore, to assess specificity for our clinical phenotype, we compared network associations among the BAS subscales and with diagnosis-specific disease severity measures (see Supplementary Methods).
50-1	7984-7995	Furthermore	_
50-2	7996-7997	,	_
50-3	7998-8000	to	_
50-4	8001-8007	assess	_
50-5	8008-8019	specificity	_
50-6	8020-8023	for	_
50-7	8024-8027	our	_
50-8	8028-8036	clinical	_
50-9	8037-8046	phenotype	_
50-10	8047-8048	,	_
50-11	8049-8051	we	_
50-12	8052-8060	compared	_
50-13	8061-8068	network	_
50-14	8069-8081	associations	_
50-15	8082-8087	among	_
50-16	8088-8091	the	_
50-17	8092-8095	BAS	_
50-18	8096-8105	subscales	_
50-19	8106-8109	and	_
50-20	8110-8114	with	_
50-21	8115-8133	diagnosis-specific	_
50-22	8134-8141	disease	_
50-23	8142-8150	severity	_
50-24	8151-8159	measures	_
50-25	8160-8161	(	_
50-26	8162-8165	see	_
50-27	8166-8179	Supplementary	_
50-28	8180-8187	Methods	_
50-29	8188-8189	)	_
50-30	8190-8191	.	_

Text=Although the above analyses accounted for variables including clinical group, age, sex and in-scanner motion, we also conducted additional analyses including smoking status as a covariate.
51-1	8192-8200	Although	_
51-2	8201-8204	the	_
51-3	8205-8210	above	_
51-4	8211-8219	analyses	_
51-5	8220-8229	accounted	_
51-6	8230-8233	for	_
51-7	8234-8243	variables	_
51-8	8244-8253	including	_
51-9	8254-8262	clinical	_
51-10	8263-8268	group	_
51-11	8269-8270	,	_
51-12	8271-8274	age	_
51-13	8275-8276	,	_
51-14	8277-8280	sex	_
51-15	8281-8284	and	_
51-16	8285-8295	in-scanner	_
51-17	8296-8302	motion	_
51-18	8303-8304	,	_
51-19	8305-8307	we	_
51-20	8308-8312	also	_
51-21	8313-8322	conducted	_
51-22	8323-8333	additional	_
51-23	8334-8342	analyses	_
51-24	8343-8352	including	_
51-25	8353-8360	smoking	_
51-26	8361-8367	status	_
51-27	8368-8370	as	_
51-28	8371-8372	a	_
51-29	8373-8382	covariate	_
51-30	8383-8384	.	_

Text=Finally, we also included composite medication load as a confound variable in network analyses, based on a previously described method.
52-1	8385-8392	Finally	_
52-2	8393-8394	,	_
52-3	8395-8397	we	_
52-4	8398-8402	also	_
52-5	8403-8411	included	_
52-6	8412-8421	composite	_
52-7	8422-8432	medication	_
52-8	8433-8437	load	_
52-9	8438-8440	as	_
52-10	8441-8442	a	_
52-11	8443-8451	confound	_
52-12	8452-8460	variable	_
52-13	8461-8463	in	_
52-14	8464-8471	network	_
52-15	8472-8480	analyses	_
52-16	8481-8482	,	_
52-17	8483-8488	based	_
52-18	8489-8491	on	_
52-19	8492-8493	a	_
52-20	8494-8504	previously	_
52-21	8505-8514	described	_
52-22	8515-8521	method	_
52-23	8522-8523	.	_

